ATE222489T1 - Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren - Google Patents
Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumorenInfo
- Publication number
- ATE222489T1 ATE222489T1 AT98955056T AT98955056T ATE222489T1 AT E222489 T1 ATE222489 T1 AT E222489T1 AT 98955056 T AT98955056 T AT 98955056T AT 98955056 T AT98955056 T AT 98955056T AT E222489 T1 ATE222489 T1 AT E222489T1
- Authority
- AT
- Austria
- Prior art keywords
- thyroxine
- malignant tumors
- ketone
- treatment
- significant hormonal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/956,711 US5922775A (en) | 1997-10-23 | 1997-10-23 | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
| PCT/US1998/022383 WO1999020263A1 (en) | 1997-10-23 | 1998-10-23 | Thyroxine analogues having no significant hormonal activity to treat malignant tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE222489T1 true ATE222489T1 (de) | 2002-09-15 |
Family
ID=25498590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98955056T ATE222489T1 (de) | 1997-10-23 | 1998-10-23 | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5922775A (de) |
| EP (1) | EP1024800B1 (de) |
| AT (1) | ATE222489T1 (de) |
| AU (1) | AU1195499A (de) |
| DE (1) | DE69807349T2 (de) |
| ES (1) | ES2181298T3 (de) |
| WO (1) | WO1999020263A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| KR20010042168A (ko) * | 1998-03-25 | 2001-05-25 | 바이오소스 테크놀로지스 인코포레이티드 | 혈관형성을 저해하는 벤조에이트 유도체 |
| US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
| US6326402B1 (en) * | 1998-08-12 | 2001-12-04 | Octamer, Inc. | Methods for treating viral infections using a compound capable of inhibiting microtubules |
| US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
| EP2428516A1 (de) * | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Neue Phosphor enthaltende Thyromimetika |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| EP1906948A4 (de) * | 2005-07-18 | 2010-03-17 | Bipar Sciences Inc | Krebsbehandlung |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| WO2008030887A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| WO2009051815A1 (en) * | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| WO2009064738A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| AU2017355402A1 (en) | 2016-11-02 | 2019-05-30 | Health Research, Inc. | Combination treatment with antibody-drug conjugates and PARP inhibitors |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| SG11201906671SA (en) * | 2017-02-03 | 2019-08-27 | Univ California | Compositions and methods for inhibiting reticulon 4 |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| WO2018237327A1 (en) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| EP3687501A4 (de) | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | Iniparib-formulierungen und verwendungen davon |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| MA53433A (fr) * | 2018-08-24 | 2021-06-30 | Xeniopro GmbH | Éthers phénoxy(hétéro)aryle à activité antiproliférative |
| EP4775207A2 (de) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Zusammensetzungen zur behandlung von fibrose |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| EP4161925A4 (de) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von lebererkrankungen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB642159A (en) * | 1947-10-23 | 1950-08-30 | Glaxo Lab Ltd | Improvements in or relating to the preparation of diphenyl ethers |
| GB643089A (en) * | 1947-10-23 | 1950-09-15 | Glaxo Lab Ltd | Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers |
| US4724234A (en) * | 1982-09-17 | 1988-02-09 | Therapeutical Systems Corp. | Method for producing oncolysis |
| US4816255A (en) * | 1985-07-31 | 1989-03-28 | Ghent William R | Treatment of iodine deficiency breast syndrome |
| GB9211415D0 (en) * | 1992-05-29 | 1992-07-15 | Ici Plc | Process for the production of purified terephthalic acid |
| US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
-
1997
- 1997-10-23 US US08/956,711 patent/US5922775A/en not_active Expired - Lifetime
-
1998
- 1998-10-23 EP EP98955056A patent/EP1024800B1/de not_active Expired - Lifetime
- 1998-10-23 AU AU11954/99A patent/AU1195499A/en not_active Abandoned
- 1998-10-23 WO PCT/US1998/022383 patent/WO1999020263A1/en not_active Ceased
- 1998-10-23 DE DE69807349T patent/DE69807349T2/de not_active Expired - Lifetime
- 1998-10-23 ES ES98955056T patent/ES2181298T3/es not_active Expired - Lifetime
- 1998-10-23 AT AT98955056T patent/ATE222489T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| AU1195499A (en) | 1999-05-10 |
| EP1024800B1 (de) | 2002-08-21 |
| DE69807349D1 (de) | 2002-09-26 |
| WO1999020263A1 (en) | 1999-04-29 |
| US5922775A (en) | 1999-07-13 |
| DE69807349T2 (de) | 2003-01-02 |
| ES2181298T3 (es) | 2003-02-16 |
| EP1024800A1 (de) | 2000-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69807349D1 (de) | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren | |
| ATE300292T1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
| DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
| ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
| DE69127175D1 (de) | Antisens-Oligonukleotide zur Behandlung von Krebs | |
| DE69839586D1 (de) | Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung | |
| ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
| DE69737066D1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
| ATE262336T1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE69532804D1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
| ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
| ATE249233T1 (de) | Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen | |
| NO994330D0 (no) | Metode for behandling av en tumor | |
| NO932101D0 (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
| ATE222119T1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
| DE3854121D1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
| ATE181240T1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen | |
| ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
| DE59911556D1 (de) | Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor | |
| DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren | |
| DE69231465D1 (de) | Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten | |
| DE69133542D1 (de) | Katheter zur Behandlung von Prostaterkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1024800 Country of ref document: EP |